Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Lemborexant in Severe Renal Impairment
NCT03443063Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Feb 2018
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lemborexant in Insomnia (2 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Maximum Observed Plasma Concentration of Lemborexant at Day 1, Area Under the Plasma Concentration-Time Curve From Time Zero to 72 Hours Post Dose of Lemborexant and 2 more. Started Feb 2018; status: completed.
02
Drugs
lemborexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT03443063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03443063.